Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.64 |
| ▸ | SCN1A | P35498 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.64 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22862890 | 0.91 | KDM4E (0.66) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL4305 | 0.90 | CYP2D6 (0.63) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL15239796 | 0.89 | KDM4E (0.64) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| Sulfuric Acid SCHEMBL19100311 | 0.87 | KDM4E (0.66) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL1612723 | 0.86 | CYP2D6 (0.60) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL8863202 | 0.86 | CYP2D6 (0.62) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| Sulfuric Acid SCHEMBL9614123 | 0.85 | KDM4E (0.67) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL2150774 | 0.85 | KDM4E (0.61) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL29645230 | 0.85 | CYP2D6 (0.59) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL4278098 | 0.84 | CYP2D6 (0.65) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-111836906-A | Classifier for identifying robust sepsis subtypes | 斯坦福大学托管董事会 | 2020-10-27 | — | — | CN | claimed |
| US-9957253-B2 | Triaminopyrimidine compounds useful for preventing or treating malaria | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2018-05-01 | — | — | US | claimed |
| EP-3137455-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV Medicines for Malaria Venture (CH) | 2017-03-08 | — | — | EP | claimed |
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | ASTRAZENECA INDIA PRIVATE LIMITED (IN) | 2017-02-23 | — | — | US | claimed |
| WO-2015165660-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-11-05 | — | — | WO | claimed |
| WO-2007008665-A1 | COMPOSITION AND THE USE THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS | PHOENIX BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-6914128-B1 | Comprises immunoglobulin for treatment and prevention of inflammatory and autoimmune diseases | ABBOTT GMBH & CO. KG (DE) | 2005-07-05 | — | — | US | claimed |
| EP-0699079-B1 | BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES COMPRISING GENETIC MATERIALS | DOW CHEMICAL CO (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1071409-B1 | USE OF ORGANOPHOSPHORIC COMPOUNDS FOR THE THERAPEUTIC AND PREVENTATIVE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2003-10-15 | — | — | EP | claimed |
| US-6331441-B1 | FOR HIGH THROUGHPUT ANALYSIS OF MULTIPLE ANALYTES IN COMPLEX MIXTURES OF SAMPLE SUBSTANCES, COMBINATORIAL ANALYSIS | GENOMETRIX GENOMICS INCORPORATED | 2001-12-18 | — | — | US | claimed |
| EP-0361894-B1 | Loading and controlled release of amphiphatic molecules to and from liposomes | YISSUM RES DEV CO (IL) | 1994-11-09 | — | — | EP | claimed |
| EP-0422097-B1 | METHOD OF INHIBITING THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN VIVO | DAVIS MICHAEL H (US) | 1994-04-27 | — | — | EP | claimed |
| US-20240238388-A1 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-07-18 | — | — | US | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240209369-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| WO-1987000195-A1 | ANIMAL CELL CULTURE | CELLTECH LIMITED (GB) | 1987-01-15 | — | — | WO | disclosed |
| WO-1986005807-A1 | TRANSFORMED MYELOMA CELL-LINE AND A PROCESS FOR THE EXPRESSION OF A GENE CODING FOR A EUKARYOTIC POLYPEPTIDE EMPLOYING SAME | CELLTECH LIMITED (GB) | 1986-10-09 | — | — | WO | disclosed |
| EP-0025721-B1 | A MEDICATION FOR ORAL ADMINISTRATION AND PROCESS FOR ITS MANUFACTURE | HOLLAND, Charles Cottrell (AU) | 1984-02-01 | — | — | EP | disclosed |
| EP-0025721-A1 | A medication for oral administration and process for its manufacture | HOLLAND, Charles Cottrell (AU) | 1981-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050951-A1 | TRIAMINOPYRIMIDINE COMPOUNDS USEFUL FOR PREVENTING OR TREATING MALARIA | DPYD, TYMP, DHFR | CYP2D6 271/4885KDM4E 2751/4885ALDH1A1 1085/4885 |
| US-20240238388-A1 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS | ELANE, MPO, MMP8 | CYP2D6 4161/4885KDM4E 3423/4885ALDH1A1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.